Literature DB >> 12853777

Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.

Robert W Allan1, Harriete Sanderson, Jonathan I Epstein.   

Abstract

PURPOSE: Few studies have examined the radical prostatectomy followup of a minute focus of adenocarcinoma on prostate needle core biopsy.
MATERIALS AND METHODS: We searched the surgical pathology data base (1999 to 2000) for patients with a minute focus of Gleason score 6 adenocarcinoma (defined as a single focus less than or equal to a 40 x microscopic field) who subsequently underwent radical retropubic prostatectomy at our institution. Potentially insignificant tumors were defined as those with a radical prostatectomy tumor volume of less than 0.5 cc, Gleason score 6 or less and organ confined disease.
RESULTS: A total of 54 patients (mean age 58 years, range 45 to 70) were evaluated. The average number of prostate cores per biopsy was 6.3. All had Gleason score 6 by study design. Mean prostate specific antigen (PSA) was 6.0 (range 0.8 to 15). Average tumor volume at radical prostatectomy was 0.39 cc. Of the 54 tumors 24 (44%) were 0.1 cc or less. Two-thirds of the tumors were clinically potentially insignificant. Using a PSA density (PSAD) cutoff of 0.15 we identified 30 of 36 patients (83%) with potentially insignificant tumors. Of those with a PSAD of 0.15 or less with clinically significant tumors, 5 of 6 still had relatively small, organ confined tumors with Gleason score less than 7.
CONCLUSIONS: In the era of PSA screening most patients with a minute focus of Gleason score 6 or less adenocarcinoma on needle biopsy had potentially insignificant tumors. However, one-third of patients had clinically significant tumors warranting definitive therapy. The smallest focus of cancer on needle biopsy is not a guarantee of a clinically insignificant tumor. PSAD may have some value within this group in guiding clinicians and patients as to the likelihood of having clinically insignificant tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853777     DOI: 10.1097/01.ju.0000074747.72993.cb

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Validation of Epstein criteria of insignificant prostate cancer in Middle East patients.

Authors:  Ihab A Hekal; Nasr A El-Tabey; Mohamed Adel Nabeeh; Ahmed El-Assmy; Mohamed Abd El-Hameed; Adel Nabeeh; Elhousseiny I Ibrahiem
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

2.  The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.

Authors:  Al B Barqawi; Ruslan Turcanu; Eduard J Gamito; Scott M Lucia; Colin I O'Donnell; E David Crawford; David D La Rosa; Francisco G La Rosa
Journal:  Int J Clin Exp Pathol       Date:  2011-06-12

3.  Recommandations de l'Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.

Authors:  Ricardo A Rendon; Ross J Mason; Karim Marzouk; Antonio Finelli; Fred Saad; Alan So; Phillipe Violette; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

Review 4.  Saturation biopsies for prostate cancer: current uses and future prospects.

Authors:  Nicolas B Delongchamps; Gabriel P Haas
Journal:  Nat Rev Urol       Date:  2009-11-10       Impact factor: 14.432

5.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

6.  Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer.

Authors:  Kwang Ho Kim; Yun Beom Kim; Jeong Kee Lee; Yoon Jung Kim; Tae Young Jung
Journal:  Korean J Urol       Date:  2010-06-21

7.  Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen.

Authors:  N B Delongchamps; G de la Roza; V Chandan; R Jones; G Threatte; M Jumbelic; G P Haas
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-07-15       Impact factor: 5.554

8.  The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL.

Authors:  Xiang-Yi Zheng; Li-Ping Xie; Yu-Yong Wang; Wei Ding; Kai Yang; Hua-Feng Shen; Jie Qin; Yu Bai; Zhao-Dian Chen
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-30       Impact factor: 4.553

9.  Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation.

Authors:  Kazutoshi Fujita; Charles M Ewing; Lori J Sokoll; Debra J Elliott; Mark Cunningham; Angelo M De Marzo; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

10.  [Clinical insignificance of prostate cancer: are there morphological findings?].

Authors:  B Helpap; L Egevad
Journal:  Urologe A       Date:  2009-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.